Weakness

Best LSAT Prep Course (2024): Blueprint Prep & Magoosh Reviewed by Better Business Advice

Retrieved on: 
Friday, March 1, 2024

This assessment focuses on two prominent LSAT prep companies, Blueprint Prep and Magoosh , both renowned for offering exceptional resources crafted by academic experts.

Key Points: 
  • This assessment focuses on two prominent LSAT prep companies, Blueprint Prep and Magoosh , both renowned for offering exceptional resources crafted by academic experts.
  • Enrolling in an LSAT prep course can offer several advantages that can significantly impact a student’s LSAT performance and overall law school application process.
  • Finding the best LSAT prep course is a crucial step in the journey toward LSAT success.
  • Better Business Advice offers an extensive review that compares the best LSAT prep courses to help students choose one that meets their needs, maximizes their potential, and helps them achieve their LSAT goals.

Donaldson Reports Record Second Quarter Fiscal Year 2024 Sales and Earnings

Retrieved on: 
Wednesday, February 28, 2024

On-Road sales decreased 3.0% and Off-Road sales decreased 13.4% due to lower global equipment production and weakness in agriculture markets.

Key Points: 
  • On-Road sales decreased 3.0% and Off-Road sales decreased 13.4% due to lower global equipment production and weakness in agriculture markets.
  • Industrial Filtration Solutions (IFS) sales grew 6.0% as a result of robust dust collection and Power Generation sales.
  • Life Sciences segment (Life Sciences) sales increased 6.0% as Disk Drive sales rebounded from weak prior year market conditions.
  • Second quarter 2023 adjusted operating expenses as a percentage of sales, which exclude restructuring and other charges, were 19.3%.

Luxfer Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Guidance

Retrieved on: 
Wednesday, February 28, 2024

Luxfer Holdings PLC (NYSE: LXFR) (“Luxfer” or the “Company”), a global industrial company innovating niche applications in materials engineering, today announced financial results for the fourth quarter and full year, ended December 31, 2023.

Key Points: 
  • Luxfer Holdings PLC (NYSE: LXFR) (“Luxfer” or the “Company”), a global industrial company innovating niche applications in materials engineering, today announced financial results for the fourth quarter and full year, ended December 31, 2023.
  • “I am also pleased with the momentum and progress made in our strategic review process, which we announced in October.
  • Fourth quarter GAAP gross profit declined $5.2 million to $16.7 million.
  • Excluding Graphic Arts, adjusted EBITDA of $8.1 million decreased 27.7%, from $11.2 million in the prior year quarter.

AM Best Affirms Credit Ratings of Mutual of America Life Insurance Company

Retrieved on: 
Friday, February 23, 2024

AM Best has affirmed the Financial Strength Rating of A (Excellent) and the Long-Term Issuer Credit Rating of “a” (Excellent) of Mutual of America Life Insurance Company (MofA) (New York, NY).

Key Points: 
  • AM Best has affirmed the Financial Strength Rating of A (Excellent) and the Long-Term Issuer Credit Rating of “a” (Excellent) of Mutual of America Life Insurance Company (MofA) (New York, NY).
  • For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best's Credit Ratings .
  • For information on the proper use of Best’s Credit Ratings, Best’s Performance Assessments, Best’s Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best’s Ratings & Assessments .
  • AM Best is a global credit rating agency, news publisher and data analytics provider specializing in the insurance industry.

AMPL Shareholder Notice: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Amplitude, Inc. Class Action

Retrieved on: 
Friday, February 23, 2024

The complaint seeks relief on behalf of the named plaintiff and all other similarly situated holders of Amplitude during the Class Period.

Key Points: 
  • The complaint seeks relief on behalf of the named plaintiff and all other similarly situated holders of Amplitude during the Class Period.
  • The named plaintiff is represented by Robbins LLP.
  • Founded in 2012, Amplitude is a technology company that helps businesses analyze data for their digital products and track customer interactions.
  • The price of Amplitude Class A stock currently trades at less than $15 per share, more than 80% below the Class Period high.

Ingevity reports fourth quarter and full year 2023 financial results

Retrieved on: 
Wednesday, February 21, 2024

Ingevity Corporation (NYSE: NGVT) today reported its financial results for the fourth quarter and full year 2023.

Key Points: 
  • Ingevity Corporation (NYSE: NGVT) today reported its financial results for the fourth quarter and full year 2023.
  • Diluted adjusted EPS in Q4 was $0.21 compared to diluted adjusted EPS of $0.57 in the prior year quarter.
  • Use of non-GAAP financial measures: This press release includes certain non‐GAAP financial measures intended to supplement, not substitute for, comparable GAAP measures.
  • Reconciliations of non‐GAAP financial measures to GAAP financial measures are provided within the Appendix to this presentation.

Enpro Reports Fourth Quarter and Full Year 2023 Results, Introduces 2024 Guidance Fourth Quarter Results Full Year 2023 Highlights

Retrieved on: 
Tuesday, February 20, 2024

Corporate expenses for 2023 of $49.5 million increased $2.5 million compared to 2022 due to an increase in total compensation expense.

Key Points: 
  • Corporate expenses for 2023 of $49.5 million increased $2.5 million compared to 2022 due to an increase in total compensation expense.
  • Income from continuing operations attributable to Enpro Inc. increased to $10.8 million, compared to $6.7 million in the prior year.
  • Adjusted income from continuing operations attributable to Enpro Inc. of $137.0 million decreased 3.4% compared to 2022.
  • Enpro will hold a conference call today, February 20, 2024, at 8:30 a.m. Eastern Time to discuss fourth quarter and full year 2023 results.

McGrath Announces Results for Fourth Quarter 2023 and Announces 33rd Annual Dividend Increase

Retrieved on: 
Wednesday, February 21, 2024

Dividend rate of $0.465 per share for the fourth quarter 2023.

Key Points: 
  • Dividend rate of $0.465 per share for the fourth quarter 2023.
  • Joe Hanna, President and CEO of McGrath, made the following comments:
    “We were pleased with our fourth quarter results.
  • All comparisons presented below are for the quarter ended December 31, 2023 to the quarter ended December 31, 2022 unless otherwise indicated.
  • For the fourth quarter of 2023, the Company’s Mobile Modular division reported Adjusted EBITDA of $54.1 million, an increase of $11.6 million, or 27%, when compared to the same quarter in 2022.

Inequalities in the face of cardiovascular risk: women the No. 1 victims

Retrieved on: 
Thursday, March 7, 2024

BOSTON, March 7, 2024 /PRNewswire/ -- Cardiovascular disease kills one women every 33 seconds in the USA10. Yet 80% of these deaths could be avoided11 through early diagnosis and awareness of symptoms and risk factors specific to women. To help reduce this excess mortality, Withings is committed to raising awareness via an exclusive survey, and providing the means to tackle their main cause: hypertension, which accounts for the majority of cardiovascular deaths.12

Key Points: 
  • Inequalities also affect health, particularly cardiovascular health: they lead to under-diagnosis and poorer care for women, resulting in avoidable excess mortality.
  • Yet 80% of these deaths could be avoided11 through early diagnosis and awareness of symptoms and risk factors specific to women.
  • Yet 50% of women are unaware of their cardiovascular risk.13
    45.9% of American women surveyed by Withings admit to putting their loved ones' health before their own.
  • Withings and cardiovascular monitoring in women: the need for a real-life, longitudinal approach
    Monitoring cardiovascular health and hypertension involves tracking a range of biomarkers.

JUVÉDERM® VOLUMA® XC For Temple Hollows Receives U.S. FDA Approval

Retrieved on: 
Tuesday, March 5, 2024

IRVINE, Calif., March 5, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the U.S. FDA approval of JUVÉDERM® VOLUMA® XC for injection in the temple region to improve moderate to severe temple hollowing in adults over the age of 21.1 JUVÉDERM® VOLUMA® XC is the first and only hyaluronic acid (HA) dermal filler to receive U.S. FDA approval for the improvement of moderate to severe temple hollowing with results lasting up to 13 months with optimal treatment.*1

Key Points: 
  • *1
    "The approval of JUVÉDERM® VOLUMA® XC to treat temple hollows further demonstrates Allergan Aesthetics commitment to innovation and addressing patient needs," said Carrie Strom, President, Allergan Aesthetics and Senior Vice President, AbbVie.
  • "This is the first U.S. FDA approval of a hyaluronic acid dermal filler for use in the upper face and addresses a real unmet need for patients."
  • The safety of JUVÉDERM® VOLUMA® XC in patients with a history of excessive scarring or pigmentation disorders has not been studied.
  • To report a side effect with any product in the JUVÉDERM® Collection, please call the Allergan® Product Support Department at 1‑877‑345‑5372.